SCHEMBL5411571

SCHEMBL5411571

CCCCc1oc2ccccc2c1Cc1ccc2c(I)c(O)ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 15/20 1.00
EYA3 Q99504 2/20 0.46
NQO1 P15559 1/20 0.42
TTR P02766 1/20 0.41
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5416428 0.88 PTPN1 (1.00) PTPN1EYA3NQO1TTR
SCHEMBL5413786 0.84 PTPN1 (1.00) PTPN1EYA3NQO1TTR
SCHEMBL5425330 0.79 PTPN1 (1.00) PTPN1
SCHEMBL6730825 0.78 PTPN1 (0.93) PTPN1EYA3TTR
SCHEMBL5764063 0.76 PTPN1 (0.83) PTPN1EYA3
SCHEMBL5420762 0.75 PTPN1 (1.00) PTPN1TTRTHRATHRB
SCHEMBL4461358 0.74 PTPN1 (0.64) PTPN1EYA3
SCHEMBL3864688 0.74 PTPN1 (0.71) PTPN1EYA3TTR
SCHEMBL5416344 0.71 PTPN1 (1.00) PTPN1
SCHEMBL4474980 0.71 PTPN1 (0.63) PTPN1EYA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291639-B2 Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2007-11-06 US claimed
US-20030013732-A1 Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2003-01-16 US claimed
WO-2003000258-A1 ARYLOXY-ACETIC ACID COMPOUNDS USEFUL AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO claimed
US-6110963-A FOR PROPHYLAXIS AND TREATMENT OF INSULIN RESISTANCE, HYPERGLYCEMIA, TYPE II DIABETES, MOLULATING GLUCOSE LEVELS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-29 US claimed
US-7291639-B2 Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2007-11-06 US disclosed
US-20030013732-A1 Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH (US) 2003-01-16 US disclosed
WO-2003000258-A1 ARYLOXY-ACETIC ACID COMPOUNDS USEFUL AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed
US-6110963-A FOR PROPHYLAXIS AND TREATMENT OF INSULIN RESISTANCE, HYPERGLYCEMIA, TYPE II DIABETES, MOLULATING GLUCOSE LEVELS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013732-A1 Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) CFH, SERPINH1, APEH PTPN1 1793/4885EYA3 3669/4885NQO1 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.